Next Biomedical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Nextbiomedical develops medical products that stop bleeding during endoscopic procedures and block blood vessels to treat tumors, using polymer and drug-delivery technology as their foundation.
Its products are used by physicians in hospitals, and it distributes them through licensing agreements with larger medical-device companies in major markets including the United States, Europe, and Japan. Listed on KOSDAQ, South Korea's tech-focused small-cap exchange, the company's commercial revenue is currently anchored by its endoscopic hemostatic powder, Nexpowder™, which is distributed globally under a licensing deal with Medtronic.
Summary is AI-generated and may contain errors · figures from DART filings
Nextbiomedical has a quality-management system partnership with Medtronic and holds domestic distribution rights through Taewong Medical for the Korean market.
Next Biomedical in five facts
What does Next Biomedical do?
Nextbiomedical develops medical products that stop bleeding during endoscopic procedures and block blood vessels to treat tumors, using polymer and drug-delivery technology as their foundation.
Where is Next Biomedical listed and in which sector?
Next Biomedical (Korean name: 넥스트바이오메디컬) trades under KRX code 389650 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is Next Biomedical?
Its market capitalisation was US$173.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Next Biomedical's latest annual revenue and operating profit?
For fiscal year 2025, Next Biomedical reported revenue of US$12.4M, an operating loss of US$543.1K and a net loss of US$234.8K, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 72.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Investor relations (IR) meetingSep 11
- Investor relations (IR) meetingSep 1
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Next Biomedical reported separate results for FY2025: revenue of US$11.2M (+72.6% year on year), an operating loss of US$500K and a net loss of US$222K (from a profit a year earlier).
Earnings · Feb 6